Overview

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)

Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This is a randomized, 12-week, double-blind, placebo-controlled, dose-ranging study in patients with IBS-C.
Phase:
Phase 2
Details
Lead Sponsor:
Bausch Health Americas, Inc.
Synergy Pharmaceuticals Inc.
Treatments:
Plecanatide